Alterity Therapeutics Limited (ATH.XA)
| Previous close | 0.0030 |
| Open | 0.0030 |
| Bid | 0.0020 x N/A |
| Ask | 0.0030 x N/A |
| Day's range | 0.0030 - 0.0030 |
| 52-week range | 0.0030 - 0.0090 |
| Volume | |
| Avg. volume | 4,398,486 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0060 |
| Earnings date | 29 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAppendix 4C – Q4 FY24 Quarterly Cash Flow Report
Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in some patientsData from the bioMUSE Natural History Study continues to characterize early stage MSA and inform Alterity’s Phase 2 clinical trialsMultiple data presentations at the World Orphan Drug Congress and the American Academy of Neurology (AAN) Annual MeetingCash balance on 30 June 2024 of A$12.6M
- GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data fo
ZacksAlterity (ATHE) Up on Interim Data From Advance MSA Study
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
